pleas refer disclosur section locat end
report analyst certif disclosur
excit launch coverag spec pharma name bhc op pt op pt
teva pp pt sector weight remain peer perform
start career associ cover compani team whove work
unbeliev hard look forward detail work that need invest
view name long term
pleas lookout weve prepar seri deep dive directli address
biggest overhang space litig side fundament side today click
initi deck model prerecord webcast min let us
know question im
price juli
bhc top pick spec pharma coverag reason
believ consensu mis-model bhc top product xifaxan
new formul label expans opportun left consensu number
also feel there upsid ip front well detail patent analysi
conclud xifaxan outer year mou patent allow exclus teva settlement
xifaxan go
wr analysi foa consensu number
see room upsid signific
estim driven aqualox bhc sihi daili dispos len well duobrii
gener agre duobrii valu proposit keep psoriasi pt expens
biolog addit adjust duobrii clinic data think efficaci otezla like
consensu estim far lower otezla clear estim
increment higher consensu theyr nowher near otezla
wr analysi foa consensu number list clinic trial
lastli model bhc slowli expand ebitda next decad allow clear
path toward de-lever turn drive earn expans outer year
understand investor frustrat management team earn lack
financi disclosur still believ your go invest gener compani long term
like best bet even model revenu flattish next year come
consensu eu busi like
imag illustr see myl na busi evolv time us gx
continu erod dont see dynam space chang anytim soon allow
myl top-line stay flattish biosimilar portfolio becom bigger part
revenu overtim potenti help margin profil long term
compani slide wr analysi
addit see room ep expans next year pay long
term debt therebi reduc interest expens myl gross margin slightli improv portfolio
becom lever toward complex gx biosimilar notabl doesnt bake top-line
lastli believ doesnt litig risk teva current opioid
litig see current pay claim regard doj civil liabil surround
price fix investig pleas stay tune weve done lot work issu
hard come buy thesi teva reason despit valuat reach new
low none surpris investor
potenti liabil surround opioid doj price investig high
potenti combin liabil investig close view
believ there decent chanc gx manufactur may ultim end win
public nuisanc claim pursu state opioid worri potenti fine
given on-going ok trial neg read across teva upcom
anoth risk teva cgrp salthough current estim slightli
consensu next year
competitor market payor forc higher gross net discount
product formulari addit despit ajovi cgrp quarterli
dose dont see adopt significantli pt meanwhil lli cgrp start
overtak teva im
issu lead us worri ajovi consensu estim impli
signific increas volum teva hit
foa consensu wr analysi
see latest updat
analyst wolf research llc primarili respons research report whose name
appear first front page research report herebi certifi recommend
opinion express research report accur reflect research analyst person
view subject secur issuer ii part research analyst compens
directli indirectli relat specif recommend view contain
report
